Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis

Clinical Infectious Diseases

Volumn 54, Issue 1, 2012, Pages 121-128

  Loyse, Angela ^a,b,c,d   Wilson, Douglas ^c   Meintjes, Graeme ^a,b,e   Jarvis, Joseph N ^d   Bicanic, Tihana ^d   Bishop, Leesa ^c   Rebe, Kevin ^a,e   Williams, Anthony ^a   Jaffar, Shabbar ^f   Bekker, Linda Gail ^b   Wood, Robin ^b   Harrison, Thomas S ^d  

^a GF Jooste Hospital   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c EDENDALE HOSPITAL   (South Africa)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e Division of Infectious Diseases and HIV Medicine   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; COLONY FORMING UNIT; COMPARATIVE STUDY; CRYPTOCOCCAL MENINGITIS; DRUG MEGADOSE; DRUG SAFETY; EARLY FUNGICIDAL ACTIVITY; FEMALE; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; PATHOGEN CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; TREATMENT OUTCOME;

EID: 84555209300     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir745     Document Type: Article

References (42)

1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
2. Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 10:67.
3. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection onmeningitis in Harare: a prospective study of 406 predominantly adult patients. AIDS 2000; 14:1401-7. (Pubitemid 30459513)
4. Gordon SB, Walsh AL, Chaponda M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000; 21:53-7. (Pubitemid 32268938)
5. Silber E, Sonnenberg P, Ho KC, et al. Meningitis in a community with a high prevalence of tuberculosis and HIV infection. J Neurol Sci 1999; 162:20-6. (Pubitemid 29064113)
6. Harrison TS. The burden of HIV-associated cryptocccal disease. AIDS 2009; 23:531-2.
7. Okongo M, Morgan D, Mayanja B, et al. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998; 27:698-702. (Pubitemid 28431516)
8. French N, Gray K, Watera C, et al. Cryptococcal meningitis in a cohort of HIV-1 infected Ugandan adults. AIDS 2002; 16:1031-8. (Pubitemid 34499426)
9. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291-322.
10. Wertheimer AI, Santella TM, Lauver HJ. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. J Int Assoc Physicians AIDS Care (Chic Ill) 2004; 3:74-9.
11. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43:2163-7. (Pubitemid 40656221)
12. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48:201-5. (Pubitemid 38340521)
13. Van Duin D, Cleare W, Zaragoza O, et al. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004; 48:2014-20. (Pubitemid 38691591)
14. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging, or refactory fungal infections. Clin Infect Dis 2003; 36:1122-31. (Pubitemid 36549632)
15. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIVassociated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-9.
16. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-7. (Pubitemid 38698379)
17. Kwon-Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea & Febiger, 1992.
18. South African HIV Clinicians Society. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis inHIV-infected patients. South Afr JHIV Med 2007: 25-35.
19. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004; 48:985-91. (Pubitemid 38280353)
20. Diamond DM, Bauer M, Daniel BE, et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for the treatment of murine cryptococcal meningitis. Antimicrobial Agents and Chemotherapy 1998; 528-33. (Pubitemid 28114803)
21. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of Amphotericin B alone or combined fluconazole in the treatment of HIV-associatedcryptococcal meningitis. Clin Infect Dis 2009; 48:1775-83.
22. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010; 50:338-44.
23. Longley N, Muzoora C, Taseera K, et al. Dose response effect of highdose fluconazole for HIV-associated cryptococcal meningitis in Southwestern Uganda. Clin Infect Dis 2008; 47:1556-61.
24. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46:393-5. (Pubitemid 351552497)
25. Haubrich RH, Haghighat D, Bozzette SA, et al. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994; 170:238-42. (Pubitemid 24186455)
26. Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:838-40. (Pubitemid 26255605)
27. Jarvis NJ, Meintjes G, Rebe K, et al. Adjunctive IFN-c immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial [abstract 40]. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Alexandria, VA: CROI, 2011.
28. Brouwer AE, Van Khan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51: 1038-42. (Pubitemid 46355292)
29. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-sensitive and-resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998; 42:471-2. (Pubitemid 28114471)
30. Serena C, Pastor FJ, Mariné M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007; 60:162-5. (Pubitemid 47073294)
31. Silva EG, Paula CR, Dias AL, et al. Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficientmice caused by fluconazole-resistant Cryptococcus neoformans.Mycopathologia 2011; 171:261-6.
32. Sabbatini S, Manfredi R, Pavoni M, Consales A, Chiodo F. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004; 158:165-71. (Pubitemid 39247032)
33. Nirenberg NE, Thompson GR, Lewis JS, Hogan BK, Patterson TF. Voriconazole use and pharmacokinetics in combination with interferon-c for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol 2010; 48:532-6.
34. Carbonara S, Regazzi M, Ciracì E, et al. Long-Term efficacy and safety of TDM-Assisted combination of voriconazole plus efavirenz in an AIDS Patient with cryptococcosis and liver cirrhosis. Ann Pharmacother 2009; 43:978-84.
35. Chang H, Lee N, Ko W. Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis 2010; 14:348-50.
36. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-58.
37. Yakiwchuk EM. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008; 42:698-703. (Pubitemid 351619942)
38. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008; 48:73-84. (Pubitemid 350292275)
39. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123.
40. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80. (Pubitemid 46984619)
41. Schaars CF, Meintjes GA, Morroni C, et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200mg/day or 400mg/day of fluconazole. BMC Infect Dis 2006; 6:118-23.
42. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-7011694-701.